<div id="readability-page-1"><div><h2>What recent performance says about InnoCare Pharma</h2> <p>InnoCare Pharma (SEHK:9969) has caught investor attention after a 4.4% move in the latest session, alongside a mixed pattern over the past week, month and past 3 months that highlights shifting sentiment toward the stock.</p> <p>Over the past week the share price shows a 6.5% decline, while the past month return sits at 12.1% and the past 3 months at 26.4%. Year to date the stock is up 17.6%, with a 1 year total return of 44.97% and a 3 year total return of 63.33%. Over 5 years, the total return is a 40.24% decline.</p> <p>See our latest analysis for InnoCare Pharma.</p> <p>The HK$14.7 share price move, with a 4.4% 1 day share price return and a 26.4% 90 day share price return against a weaker recent 7 day patch, points to momentum that has been building over the medium term despite earlier long term volatility shown in the 5 year total shareholder return.</p> <p>If you are weighing InnoCare Pharma's recent swing, it can be helpful to compare it with other healthcare names by scanning 127 healthcare AI stocks</p> <p>With InnoCare Pharma trading at HK$14.70 against an indicated intrinsic value gap of about 59% and a sizeable discount to analyst targets, you have to ask: is this a genuine opportunity, or is the market already pricing in future growth?</p> <h2>Most Popular Narrative: 30.9% Undervalued</h2> <p>At HK$14.70, the most followed narrative places InnoCare Pharma's fair value at HK$21.27, which points to a sizeable valuation gap built on specific growth and profitability assumptions.</p> <blockquote> <p><em>The analysts have a consensus price target of HK$15.606 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$25.79, and the most bearish reporting a price target of just HK$8.2.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious what justifies a fair value meaningfully above HK$14.70? The narrative rests on assumptions of aggressive revenue expansion, a sharp swing in profitability and a future earnings multiple often associated with high growth stories.</p> <p><strong>Result: Fair Value of HK$21.27 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this hinges on high biotech R&amp;D spend paying off and key drugs gaining traction, while competition and pipeline setbacks could quickly weaken that bullish setup.</p> <p>Find out about the key risks to this InnoCare Pharma narrative.</p> <h2>Next Steps</h2> <p>With mixed signals across valuation, risks and rewards, what does the balance look like to you, and how quickly do you want to form a view based on the underlying data? To stress test your thinking against both the upside and the concerns flagged by the market, start by checking the 4 key rewards and 2 important warning signs</p> <h2>Looking for more investment ideas?</h2> <p>If you stop with just one company, you might miss opportunities right in front of you. Use the Simply Wall St Screener to quickly surface fresh ideas tailored to your style.</p> <ul> <li>Spot potential mispriced opportunities early by scanning 230 high quality undervalued stocks that combine quality fundamentals with room for a re rating.</li> <li>Strengthen your focus on resilience by checking 310 resilient stocks with low risk scores that score well on stability and balance sheet strength.</li> <li>Get ahead of the crowd by reviewing the screener containing 564 high quality undiscovered gems before they end up on everyone else's radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

09969

159892

159992

520880

513120

159316

520690

<p>InnoCare Pharma (SEHK:9969) has seen a 4.4% share price increase recently, with a mixed performance over the past week, month, and three months. The stock is up 17.6% year-to-date and has a one-year total return of 44.97%. Analysts suggest a fair value of HK$21.27, indicating it is undervalued at the current price of HK$14.70, with a significant intrinsic value gap of 59%. However, there is disagreement among analysts regarding future price targets, ranging from HK$8.2 to HK$25.79, reflecting varying expectations of growth and profitability.</p>

Simplywall

INNOCARE

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

InnoCare Pharma

A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Momentum And Analyst Discount